Polymorphisms of the tumour necrosis factor-α gene, coronary heart disease and obesity

European Journal of Clinical Investigation

Volumn 28, Issue 1, 1998, Pages 59-66

  Herrmann, S M ^a   Ricard, S ^a   Nicaud, V ^a   Mallet, C ^a   Arveiler, D ^b   Evans, A ^c   Ruidavets, J B ^d   Luc, G ^e   Bara, L ^f   Parra, H J ^a   Poirier, O ^a   Cambien, F ^a  

^a INSERM   (France)

^b MONICA Project   (France)

^c MONICA Project   (United Kingdom)

^d MONICA Project   (France)

^e MONICA Project   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Gene polymorphism; Myocardial infarction; Obesity; Plasma lipoproteins; TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; ISCHEMIC HEART DISEASE; MALE; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FRANCE; HLA-DR3 ANTIGEN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NORTHERN IRELAND; OBESITY; POLYMORPHISM, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15444348298     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00244.x     Document Type: Article

References (48)

1. Old LJ. Tumour necrosis factor (TNF). Science, 1985; 230: 630-632.
2. Kawakami M, Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. Journal of Experimental Medicine, 1981; 154: 631-639.
3. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced raw 264.7 cells. Journal of Experimental Medicine, 1985; 161: 984-995.
4. Matthews N. Tumour-necrosis factor from the rabbit. II. Production by monocytes. British Journal of Cancer, 1978; 38: 310-315.
5. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes, 1992; 41 (Suppl. 2): 97-101.
6. Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumour necrosis factor on lipoprotein lipase in vivo. Journal of Biological Chemistry, 1987; 262: 8390-8394.
7. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumour necrosis factor-α in human obesity and insulin resistance. Journal of Clinical Investigation, 1995; 95: 2409-2415.
8. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumour necrosis factor-α; direct role in obesity-linked insulin resistance. Science, 1993; 259: 87-91.
9. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumour necrosis factor in human adipose tissue. Journal of Clinical Investigation, 1995; 95: 2111-2119.
10. Norman RA, Bogardus C, Ravussin E. Linkage between obesity and a marker near the tumour necrosis factor-α locus in Pima Indians. Journal of Clinical Investigation, 1995; 96: 158-162.
11. Munker R, Gasson J, Ogawa M, Koeffler HP. Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature, 1986; 323: 79-82.
12. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumour necrosis factor. Journal of Experimental Medicine, 1986; 163: 740-745.
13. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature, 1987; 329: 630-632.
14. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumour necrosis factor in human atheroma. American Journal of Cardiology, 1990; 65: 297-302.
15. Vaddi K, Nicolini FA, Mehta P, Mehta JL. Increased secretion of tumour necrosis factor-α and interferon-γ by mononuclear leukocytes in patients with ischemic heart disease: relevance in superoxide anion generation. Circulation, 1995; 90: 694-699.
16. Arakawa T, Yphantis DA. Molecular weight of recombinant human tumour necrosis factor-α. Journal of Biological Chemistry, 1987; 262: 7484-7485.
17. Aggarwal BB, Kohr WJ, Hass PE et al. Human tumour necrosis factor. Journal of Biological Chemistry, 1985; 260: 2345-2354.
18. Nedwin GE, Naylor SL, Sakaguchi AY et al. Human lymphotoxin and tumour necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Research, 1985; 13: 6361-6373.
19. Carroll MC, Katzman P, Alicot EM et al. Linkage map of the human major histocompatibility complex including the tumour necrosis factor genes. Proceedings of the National Academy of Sciences of the USA, 1987; 84: 8535-8539.
20. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature, 1986; 320: 584-588.
21. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumour necrosis factor alpha promoter on transcriptional activation. Proceedings of the National Academy of Sciences of the USA, 1997; 94: 3195-3199.
22. McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwjatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature, 1994; 371: 508-511.
23. Cabrera M, Shaw MA, Sharples C et al. Polymorphism in tumour necrosis factor genes associated with mucocutaneous leishmaniasis. Journal of Experimental Medicine, 1995; 182: 1259-1264.
24. Parra HJ, Arveiler D, Evans AE et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM Study. Arteriosclerosis and Thrombosis, 1992; 12: 701-707.
25. WHO MONICA Project principal investigators. The World Health Organization MONICA project (MONItoring trends and determinants in CArdiovascular disease): A major international collaboration. Journal of Clinical Epidemiology, 1988; 41: 105-114.
26. Kee F, Tiret L, Robo JY et al. Reliability of reported family history of myocardial infarction. British Medical Journal, 1993; 307: 1528-1530.
27. Lane A, Green F, Scarabin PYet al. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM Study. Atherosclerosis, 1996; 119: 119-127.
28. Ye S, Green FR, Henney AM et al. Genetic variation in the promoter of the plasminogen activator inhibitor rype-1 (PAI-1) gene in relation to plasma PAI-1 activity and risk of myocardial infarction: the ECTIM Study. Thrombosis and Haemostasis, 1995; 74: 837-841.
29. Scarabin PY, Barra L, Ricard S et al. Genetic variation at the β fibrinogen gene in relation to plasma fibrinogen concentrations and risk of myocardial infarction. Arteriosclerosis and Thrombosis, 1993; 13: 886-891.
30. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphism. Proceedings of the National Academy of Sciences of the USA, 1989; 86: 2766-2770.
31. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences of the USA, 1977; 74: 5463-5467.
32. Saiki RK. Genetic analysis of enzymatically amplified β-globin and HLA-DQA genomic DNA with allele specific oligonucleotide probes. Nature, 1987; 324: 163-166.
33. Wilson AG, Gordon C, di Giovine FS et al. A genetic association between systemic lupus erythematodes and tumour necrosis factor alpha. European Journal of Immunology, 1994; 24: 191-195.
34. Giphart MJ, Verduijn W. The Eurotransplant HLA-DRB oligucleotide typing set. European Journal of Immunogenetics, 1991; 18: 57-68.
35. Nei M. Molecular Evolutionary Genetics. New York: Columbia University Press, 1987.
36. MacLean CJ, Morton NE. Estimation of MYRIAD haplotype frequencies. Genetics and Epidemiology, 1985; 2: 263-272.
37. Wilson AG, de Vries N, Poicot F, di Giovine FS, van der Putte LBA, Duff GW. An allelic polymorphism within the human tumour necrosis factor-α promoter region is strongly associated with HLA A1, B8, DR3 alleles. Journal of Experimental Medicine, 1993; 177: 557-560.
38. Luc G, Bard J-M, Arveiler D et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arteriosclerosis and Thrombosis, 1994; 14: 1412-1419.
39. Morin L, Schlaepfer IR, Eckel RH. Tumour necrosis factor-α eliminates binding of NF-Y and an octamer-binding protein to the lipoprotein lipase promoter in 3T3-Ll adipocytes. Journal of Clinical Investigation, 1995; 95: 1684-1689.
40. Starnes HR Jr, Warren RS, Jeevanadem M et al. Tumour necrosis factor and the acute metabolic response to injury in man. Journal of Clinical Investigation, 1988; 82: 1321-1325.
41. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science, 1996; 271: 665-668.
42. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. TNF-α inhibits signaling from insulin receptor. Proceedings of the National Academy of Sciences of the USA, 1994; 91: 4845-4858.
43. Lopez-Virella MF, Virella G. Atherosclerosis and autoimmunity. Clinical Immunology and Immunopathology, 1994; 73: 155-167.
44. Paleolog EM, Delasalle SA, Buurman WA, Feldmann M. Functional activities of receptors for tumour necrosis factor-alpha on human vascular endothelial cells. Blood, 1994; 84: 2578-2590.
45. Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA. Two distinct monokines, interleukin-1 and tumour necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. Journal of Immunology, 1986; 136: 1680-1687.
46. Couffinhal T, Duplaa C, Moreau C, Lamaziere JM, Bonnet J. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circulation Research, 1994; 74: 225-234.
47. Olefsky JM, Molina JM. Insulin resistance in man. In: Rifkin H Porte JD, eds. Diabetes Mellitus. New York: Elsevier Science Publishing, 1990: 121-153.
48. Hamann A, Mantzoros C, Vidal-Puig A, Flier JS. Genetic variability in the TNF-α promoter is not associated with type II diabetes mellitus (NIDDM). Biochemical and Biophysical Research Communications, 1995; 211: 833-839.